Cary, N.C. , Sept. 10, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Sanofi as a limited specialty pharmacy provider for WAYRILZ™ (rilzabrutinib), an oral Bruton tyrosine kinase (BTK) inhibitor for the treatment of adults with persistent or chronic immune thrombocytopenia (ITP), a rare condition of complex immune dysregulation in which platelets are targeted and destroyed by the immune system.
“Biologics by McKesson is honored to have been selected by Sanofi as a specialty pharmacy for WAYRILZ,” says George Paschal, senior director, business development, Biologics by McKesson. “Immune thrombocytopenia is a rare immune dysregulation condition that can result in bleeding risks, impair quality of life, and carry the emotional toll of ongoing treatment. The approval of WAYRILZ offers new hope for patients who have not responded to a prior treatment. We are honored to support access to this important therapy and remain committed to delivering compassionate, high-touch care for patients living with rare diseases.”
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, the Biologics’ pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For the full prescribing information for WAYRILZ™, please visit https://products.sanofi.us/wayrilz/wayrilz.pdf. For more information about the treatment of patients with ITP, please visit https://pro.campus.sanofi/us/products/wayrilz.